FDA is investigating Sarepta’s Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.
Latest Ratings for SRPT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Mar 2022 | RBC Capital | Maintains | Outperform | |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight |
